Ketolides - Telithromycin, an example of a new class of antibacterial agents

Clinical Microbiology and Infection

Volumn 6, Issue 12, 2000, Pages 661-669

  Bryskier, A ^a  

^a SANOFI   (France)

Author keywords

ABT 773; Ketolides; Telithromycin

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAMASE; CARBAMIC ACID DERIVATIVE; CETHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; ERYTHRONOLIDE A; GENTAMICIN; KETOLIDE; LINEZOLID; MACROLIDE; METICILLIN; NARBOMYCIN; OFLOXACIN; OXACILLIN; PENICILLIN G; PIKROMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; RU 69874; SENFETRINEM; TE 802; TE 810; TELITHROMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG TOLERABILITY; GRAM POSITIVE COCCI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RIBOSOME;

ANIMALIA; ILEX COOKII; POSIBACTERIA;

EID: 0034583884     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2000.00185.x     Document Type: Article

References (59)

1. Classification and structure-activity relationships of macrolides with emphasis on new development
2. Ilotycin, a new antibiotic
3. Acid stability of new macrolides
4. New directions for macrolide antibiotics
5. Antibacterial activity of roxithromycin, a laboratory evaluation
6. Chemical modification of erythromycin. Synthesis and antibacterial activity of 6-O-methyl erythromycin A
7. Azalides: A new medicinal chemical family
8. Ketolide: Novel antibacterial agent designed to overcome erythromycin A resistance
9. B resistance phenotype
10. Macrolide resistance in Staphylococcus aureus: Inducers of macrolide resistance
11. Modification of macrolide antibiotics. Synthesis of 11-deoxy-11 (carboxy amino)-6-O-methyl erythromycin A 11,12-C cyclic esters) via an intramolecular Michael reaction of O-carbamate with an α-β-unsaturated ketone
12. Novelties in the field of antibacterials
13. Ketolides: New semisynthetic 14-membered-ring macrolides
14. Synthesis and antibacterial activity of HMR 3647, a new ketolide highly potent against erythromycin resistant and susceptible pathogens
15. Novelties in the field of anti-infectives in 1997
16. Design, synthesis and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens
17. The comparative in vitro activity of HMR 3647, a ketolide antimicrobial, against clinical bacterial isolates
18. In. vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany
19. In vitro activity of the ketolide HMR 3647 (RU 66647) for Legionella spp. Its pharmacokinetics in guinea pigs and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
20. In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella bacilliformis, Ehrlichia chaffeensis
21. The macrolide-ketolide antibiotic binding site is formed by structures in domain II and V of 23S ribosomal RNA
22. Inhibitor of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics
23. Effect of antibiotics on large ribosomal subunit assembly reveals possible function of 5S rRNA
24. A ketolide resistance mutation in domain II of 23S rRNA reveals proximity of hairpin 35 to the peptidyl transferase centre
25. Interaction between HMR 3647, a new ketolide and human polymorphonuclear neutrophils
26. Effect of pro-inflammatory cytokines on the interplay between roxithromycin, HMR 3647, HMR 3004 and human polymorphonuclear neutrophils
27. Macrolide resistance
28. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system
29. Inducible erythromycin-resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family
30. B resistance induction by the ketolide telithromycin (HMR 3647): Role of the 3-keto group
31. Comparative in vitro activity of HMR 3647, a new ketolide antibiotic, against S. aureus and coagulase negative staphylococci
32. 90 studies and killing kinetics against key respiratory tract pathogens
33. Cloning and sequencing of a plasmid-mediated erythromycin resistance determinant from Staphylococcus xylosus
34. Staphylococci harboring msrA/B efflux genes: Comparative susceptibility to macrolides and related drugs
35. Susceptibility of Streptococcus mitis and Streptococcus oralis to a new ketolide, HMR 3647
36. Incidence of mef A and mef E genes in viridans group streptococci
37. Presence of mef A and mef E genes in Streptococcus agalactiae
38. Marked in vitro activity of the ketolide telithromycin (HMR 3647) against erythromycin resistant cutaneous Propionobacterium from around the world
39. A joint mutation associated with bacterial, macrolide resistance is present in both 23SrRNA genes of an erythromycin-resistant Treponema pallidum clinical isolate
40. Macrolide and ketolide resistance in clinical strains of Streptococcus pneumoniae: Mutations in 23SrRNA and L4 ribosomal protein
41. In vitro selection of resistance to telithromycin (HMR 3647), clindamycin, pristinamycin and four macrolides in Streptococcus pneumoniae
42. The bactericidal activities of HMR 3004, HMR 3647 and erythromycin against Gram-positive bacilli and development of resistance
43. Susceptibilities of penicillin and erythromycin-susceptible and resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
44. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and post antibiotic effect
45. Postantibiotic effects and the dosing of macrolides, azalides and streptogramins
46. In vivo pharmacodynamic activity of HMR 3647, a new ketolide
47. Pharmacokinetics of 800 mg once-daily dosing of the ketolide, HMR3647, in healthy young volunteers
48. The bioavailability of HMR 3647, a new once-daily ketolide antimicrobial is unaffected by food
49. Oral bioavailability of the ketolide telithromycin (HMR 3647) is similar in both elderly and young subjects
50. The ketolide antimicrobial HMR 3647 is metabolised and eliminated predominantly in the faeces in man
51. HMR 3647, a new ketolide antimicrobial, does not inhibit cytochrome P-450 activity in vitro
52. Pharmacokinetic profile of the new ketolide antimicrobial, HMR 3647, 800 mg once-daily in elderly volunteers
53. Telithromycin (HMR 3647), the first ketolide antimicrobial, does not require dosage adjustment in individuals with hepatic impairment
54. In vitro activity of ABT 773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
55. In. vitro activity of ABT773, a new ketolide antibiotic, against Chlamydia pneumoniae
56. Novelties in the field of macrolides